Table 1. Clinical studies in which Intanza 9 μg was evaluated in adults 18 to 59 y of age.

Clinical trial registration no.	Influenza season	Phase	Number of subjects	Reference
NCT00703651	2005/06 (year 3 of 3)a	II	828	Beran et al. 200955
NCT00258934	2005/06	II	978	Leroux-Roels et al. 200856
NCT00383539	2006/07	III	2255	Arnou et al. 201057

^a The final version of Intanza 9 μg was used only in the last year of this 3-y study.